

PRESS RELEASE**Strata Partners advises on the sale of Maryland, US-based Xceleron Inc. to Pharmaron****London, 12 January, 2017**

Strata Partners is delighted to announce the sale of Xceleron Inc., the Maryland, US-based globally leading Accelerator Mass Spectrometry (AMS) specialist for life sciences, to Pharmaron, a fully integrated contract research organisation offering R&D services for the life science industry with over 4,000 employees, and operations in China, the United States, and the United Kingdom. Commercial details of the transaction are not being disclosed.

Xceleron, located in Germantown, Maryland, pioneered and developed the robust use of ¹⁴C microtracers and AMS analytical technology in pharmaceutical R&D. Since 1998, Xceleron has designed new preclinical and clinical investigations around the unique analytical features of AMS. With increased adoption, Xceleron developed a proprietary approach to ensure analytical robustness at very low levels of detection compared to complementary traditional platforms such as LC-MS/MS and Liquid Scintillation Counting. Benefiting from Xceleron's work, AMS detection is now widely accepted as a valuable analytical tool in the quest for improved efficiency in pharmaceutical R&D.

Xceleron's use of microtracers and AMS detection technology complements Pharmaron's existing platforms of radiolabelled compound manufacturing and radiolabelled metabolism. The acquisition is part of Pharmaron's strategy to provide fully integrated, end-to-end R&D services.

Ed Lascelles, Partner at Albion Ventures, Xceleron's principal investor, commented: "Strata did an exceptional job on this important project, both in finding Pharmaron as a buyer for Xceleron, and in managing a complex cross-border deal from inception through to a successful conclusion. Once again, Strata Partners has delivered."

Mark Sargeant, Partner at Strata added: "The successful sale of Xceleron provides yet another example of Strata's ability to find the very best buyers globally for advanced laboratory testing technologies and analytical service providers. The combination of Xceleron's AMS technology with Pharmaron's extensive and growing R&D capabilities offers compelling opportunities for both parties."

###

For more information, please contact:

Mark Sargeant
Partner, Strata Partners
mark.sargeant@strata-partners.com
+44 (0) 207 730 1200

About Strata Partners

Founded in 2002, Strata Partners is an independent corporate finance partnership headquartered in London that provides buy side and sell side mergers & acquisitions advice and capital raising services to technology and science-enabled businesses across the globe. Learn more about Strata at: www.strata-partners.com